CSF1R and colorectal carcinoma: A total of 109 stage III or high-risk stage II CRC patients enrolled in the CIPN study were used to study the potential mechanism mediating the different clinical outcome between patients with CSF1R c.1085 genotype A_A and A_G (Figure S1).